Indexes
Blog / Thematic investing 7 min read

Best Biotech ETF Ranked by Fee and What Each Fund Really Holds

XBI is cheapest at 0.35% and holds no name above 1.49%, while IBB puts 27.7% in four large companies and ARKG is 53.1% diagnostics and lab tools. Four biotech ETFs sorted from SEC holdings.

November 2026 · Indexes

Index Studio
· vs
Index
✓Hypothetical backtest against
Holdings

Pick 2 to 10 holdings. Stocks, ETFs and crypto mix in one index.

Weighting
Performance Index
Price return
--
Vs
--
Max drawdown
--

The backtest did not run just now. Tap Backtest it to try again.

Tracking, daily closes

Educational only · Never places a trade

The cheapest biotech ETF is XBI at 0.35%, and it is also the one with the least concentration, since its largest position is 1.49% and the ten largest are 13.3% of the fund. IBB costs 0.44% and puts 27.7% in four companies (Vertex, Amgen, Gilead and Regeneron). ARKG at 0.75% is more than half diagnostics and lab tools, and FBT at 0.55% sits between the two.

Four funds come up when people search for a biotech ETF: XBI, IBB, ARKG and FBT. They all say biotech, and they hold very different things. We pulled each fund's latest N-PORT filing from the SEC and sorted every equity position, so the table below is what the funds owned on the report date, not what the fund pages say they track.

Biotech ETFs ranked by expense ratio

RankETFExpense ratioCost on $10,000Cost on $50,000Stocks heldNet assets
1SPDR S&P Biotech (XBI)0.35%$35$175152$10.73 billion (June 30)
2iShares Biotechnology (IBB)0.44%$44$220239$9.09 billion (June 30)
3First Trust NYSE Arca Biotechnology (FBT)0.55%$55$27530$2.81 billion (June 30)
4ARK Genomic Revolution (ARKG)0.75%$75$37532$1.56 billion (July 31)

XBI and FBT fees are from the issuers' fund pages. IBB and ARKG fees are from fund data aggregators, so confirm them on the iShares and ARK pages before you buy. Stock counts and net assets come from the N-PORT filings with the report date shown, so they trail the issuers' sites.

What is the cheapest biotech ETF?

The cheapest biotech ETF in this group is XBI at 0.35% a year, then IBB at 0.44%, FBT at 0.55% and ARKG at 0.75%. On $50,000 the gap between XBI and ARKG is $200 a year. XBI is also the most diversified, so the cheapest fund is a different bet from the others rather than the same bet for less.

Which biotech ETF holds the large profitable companies?

IBB, by a wide margin. It weights by company size, so Vertex was 8.08%, Amgen 7.83%, Gilead 6.84% and Regeneron 4.91%, together 27.7% of the fund. XBI is modified equal weight: the same four are 4.0% of it, and its biggest position was Apogee Therapeutics at 1.49%. If you want the established, profitable biotechs, XBI barely holds them. If you want small clinical-stage companies that live or die on a trial result, IBB barely holds those.

Biotech ETFs ranked by what they hold

We sorted each fund's equity positions into three groups: the four large profitable companies named above, diagnostics and lab tools (Illumina, Natera, 10x Genomics, Twist, Bruker, Veracyte and similar), and everything else, which is mainly drug developers. This is our classification, so the lines can be argued, but the spread between funds is far larger than any boundary case.

ETFVertex, Amgen, Gilead, RegeneronDiagnostics and lab toolsOther drug developersTen largest positionsFee per $100 of drug developers
XBI4.0%3.7%92.2%13.3%$0.36
IBB27.7%8.5%63.8%44.7%$0.48
FBT10.6%25.7%63.7%43.2%$0.74
ARKG0.0%53.1%46.9%59.1%$1.60

The last column is our arithmetic, not a number any issuer publishes: the expense ratio divided by the share held in the four large companies plus other drug developers. It is a way to see that ARKG's 0.75% buys a genomics and diagnostics tilt, not a biotech drug basket.

What is the difference between XBI and IBB?

XBI is modified equal weight and IBB is weighted by company size. XBI holds about 150 stocks with none above 1.49%, and IBB holds about 240 with Vertex alone at 8.08%. They share 41.6% of their money. In a year when the large profitable names lead, IBB wins by construction. In a year when small drug developers rally on trial data or takeover news, XBI wins by construction. Neither is a mistake, and neither is neutral.

What does ARKG hold?

ARKG held 32 stocks on July 31, 2026, and the largest were 10x Genomics at 9.39%, Twist Bioscience 7.73%, Tempus AI 6.56%, CRISPR Therapeutics 6.29% and Personalis 5.47%. The ten largest were 59.1% of the fund. Roughly half of it is diagnostics and lab tools companies, and it holds none of Vertex, Amgen, Gilead or Regeneron. It overlaps XBI and IBB by only about 10%.

What does FBT hold?

FBT is a 30-stock fund with a modified equal weight, so the largest position was only 5.6% (Corcept Therapeutics), followed by NeoGenomics 5.12%, Veracyte 5.10% and Bruker 4.32%. About a quarter of it is diagnostics and lab tools, and it holds all four large profitable names at 2.2% to 3.1% each. It shares 40.2% of its money with IBB.

Which biotech ETF fits what you want

If you wantLook atWhy
The cheapest and most diversified fundXBI0.35%, 152 stocks, ten largest 13.3%
The large profitable biotechsIBB27.7% in Vertex, Amgen, Gilead and Regeneron
Diagnostics and lab toolsARKG53.1% in tools companies, but 0.75%
A short, balanced listFBT30 stocks, no position above 5.6%

When is owning biotech stocks cheaper than a biotech ETF?

Only two companies sit in all four funds, Natera and Veracyte, and both are diagnostics. The funds agree about almost nothing else, which is the argument for deciding the mix yourself: how much goes to the large profitable names, how much to clinical-stage developers and how much to tools.

A fund charges 0.35% to 0.75% a year to hold names at weights its index sets. At 0.44%, IBB costs $440 a year on $100,000. Our software costs $288 a year on the yearly Starter plan, so building the basket yourself is cheaper than IBB above roughly $65,000 and cheaper than XBI above roughly $82,000, before your broker's costs. Below that, a fund is cheaper.

Test the mix before you commit money. On the build your own ETF tool you pick the companies and weights, backtest the basket over real market history against XBI or the S&P 500, and track it. A capped equal weight index stops one name from dominating, which is exactly what IBB does not do. The full walk-through is on the biotech stocks index page, and the holdings method is the same one we used for the gold miners ETF ranking and the ETF overlap calculator.

Before you buy any of these: biotech stocks move sharply on trial results, and a backtest is hypothetical and does not predict future returns. Selling a fund or stock at a loss and buying a near copy inside 30 days can trigger the IRS wash sale rule, so check it first.

How we built these numbers

We downloaded each fund's latest N-PORT filing from the SEC's EDGAR database (report dates June 30, 2026 for XBI, IBB and FBT and July 31, 2026 for ARKG) and counted equity positions only, which leaves out securities lending collateral. Expense ratios for XBI come from State Street's fund page and for FBT from First Trust. IBB and ARKG fees are from fund data aggregators. Overlap is the sum of the smaller weight of each company held by both funds, matched by the first two words of the company name. Indexes is index construction and backtesting software, not an adviser or a broker, and this article is not investment advice.

Build your index and see how it backtests

Bundle stocks or crypto into your own weighted index, backtest it against real market history, and track it against the S&P 500 or BTC. Educational and informational only, and Indexes never places a trade.